Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,042.11
-4.81 (-0.46%)
Streaming Delayed Price
Updated: 2:06 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
40
41
Next >
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
December 24, 2022
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while.
Via
The Motley Fool
Tuesday Talk: Where is Santa?
December 20, 2022
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.
Via
Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
December 19, 2022
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Via
Talk Markets
2 Best Biotech Stocks to Buy Right Now
December 16, 2022
Demand for medicines and vaccines has nowhere to go but up over the long run.
Via
The Motley Fool
Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis
December 15, 2022
Via
Benzinga
Regeneron Reveals An Early Cut Data From Follicular Lymphoma Study At ASH Meeting
December 13, 2022
Via
Benzinga
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
November 17, 2022
Via
Benzinga
Regeneron Pharmaceuticals's Return On Capital Employed Overview
November 17, 2022
Via
Benzinga
3 Mid-Caps That Could Double in 2023
December 15, 2022
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months.
Via
MarketBeat
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space
December 12, 2022
Via
Benzinga
Our 7 Top Biotech Stock Picks for 2023
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
Will This Potential Approval Be a Winner for Sanofi's Shareholders?
December 09, 2022
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.
Via
The Motley Fool
Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
December 08, 2022
Read the latest report on Sunshine Biopharma here.
Via
Benzinga
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
Both are riding the wave of major clinical wins
Via
The Motley Fool
Regeneron's Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol
November 30, 2022
Via
Benzinga
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
November 30, 2022
Via
Benzinga
2 Market-Beating Stocks That Can Continue Rising in 2023
November 30, 2022
It's not too late to get in on the potential 2023 growth for these two stocks.
Via
The Motley Fool
Market Currents: Why Pick Stocks?
November 28, 2022
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...
Via
Talk Markets
Stock Market Investing Action Plan: What Part Of November Don't You Understand?
November 25, 2022
A turnabout month left the market sitting on some nice gains. The next week's data might determine whether those gains hold.
Via
Investor's Business Daily
Dexcom Leads 5 Stocks Near Buy Points
November 25, 2022
They combine strong technicals and generally sound fundamentals.
Via
Investor's Business Daily
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
November 18, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."
Via
Benzinga
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
November 17, 2022
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range
Via
Spotlight Growth
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
November 17, 2022
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN).
Via
InvestorPlace
Daily Stock Analysis: Sanofi - November 2022 Snapshot
November 16, 2022
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic...
Via
Talk Markets
2 Top Biotech Stocks to Buy in November
November 12, 2022
Both of these companies have potential catalysts on the way.
Via
The Motley Fool
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
November 10, 2022
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.
Via
Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today
November 10, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.17% on an annualized basis producing an average annual return of 27.88%. Currently, Regeneron...
Via
Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
November 04, 2022
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven.
Via
InvestorPlace
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.